Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Under Armour Inc Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Under Armour Inc Class A trades at $6.72 (market cap $2.86B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.9× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UAA | |
|---|---|---|
Market Cap | $39.89B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $8.14 |
52-Week Low | $278.09 | $4.17 |
Enterprise Value | $38.15B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Under Armour (UAA) trades at $6.79, up 3.03% today, showing technical bullish momentum with moving averages supporting upward movement. However, the company faces fundamental challenges with negative net income margins (-9.98%) and declining revenue from $5.7B in 2024 to $5.2B in 2025. Recent earnings showed mixed results with a Q1 2026 miss, while cash flow remains negative at -$362M for 2025. The Dodge collaboration and Persona AI partnership represent strategic initiatives amid ongoing North American market weakness.
The outlook remains cautious with analyst consensus price target at $5.96 below current levels, reflecting concerns about profitability and revenue trends. Investment opportunity exists if international growth and cost management improve margins, but risks include persistent North American weakness, margin pressure, and negative cash flow generation. Wall Street sentiment leans neutral with 58% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
